News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,728 Results
Type
Article (607)
Company Profile (4)
Press Release (18117)
Section
Business (10221)
Career Advice (11)
Deals (1584)
Drug Delivery (3)
Drug Development (1311)
Employer Resources (2)
FDA (215)
Job Trends (572)
News (12449)
Policy (437)
Tag
Academia (42)
Accelerated approval (1)
Allergies (7)
Alliances (603)
ALS (8)
Alzheimer's disease (35)
Antibody-drug conjugate (ADC) (12)
Approvals (229)
Artificial intelligence (5)
Autoimmune disease (5)
Automation (1)
Bankruptcy (5)
Best Places to Work (514)
Biosimilars (4)
Biotechnology (1)
Bladder cancer (8)
Breast cancer (18)
Cancer (139)
Cardiovascular disease (10)
Career advice (12)
CAR-T (4)
CDC (1)
Cell therapy (11)
Cervical cancer (2)
Clinical research (1258)
Collaboration (32)
Compensation (17)
Complete response letters (2)
COVID-19 (49)
CRISPR (2)
C-suite (14)
Cystic fibrosis (5)
Data (207)
Depression (5)
Diabetes (10)
Diagnostics (215)
Digital health (3)
Diversity, equity & inclusion (1)
Drug discovery (4)
Drug pricing (4)
Duchenne muscular dystrophy (20)
Earnings (10334)
Editorial (2)
Employer resources (2)
Events (1080)
Executive appointments (12)
FDA (397)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (5)
Funding (50)
Gene editing (5)
Generative AI (1)
Gene therapy (12)
GLP-1 (31)
Government (46)
Guidances (123)
Healthcare (618)
HIV (1)
IgA nephropathy (3)
Immunology and inflammation (8)
Immuno-oncology (1)
Indications (6)
Infectious disease (63)
Inflammatory bowel disease (4)
Inflation Reduction Act (1)
Influenza (3)
Intellectual property (6)
Interviews (1)
IPO (1198)
IRA (1)
Job creations (100)
Job search strategy (8)
Labor market (2)
Layoffs (12)
Legal (68)
Liver cancer (4)
Longevity (1)
Lung cancer (12)
Lymphoma (14)
Manufacturing (19)
MASH (7)
Medical device (603)
Medtech (606)
Mergers & acquisitions (417)
Metabolic disorders (39)
mRNA (1)
Multiple sclerosis (5)
NASH (1)
Neurodegenerative disease (11)
Neuropsychiatric disorders (3)
Neuroscience (72)
NextGen: Class of 2026 (162)
Non-profit (67)
Now hiring (3)
Obesity (21)
Opinion (7)
Ovarian cancer (5)
Pain (1)
Pancreatic cancer (8)
Parkinson's disease (7)
Patents (8)
Patient recruitment (7)
Peanut (5)
People (475)
Pharmacy benefit managers (2)
Phase 1 (271)
Phase 2 (519)
Phase 3 (564)
Pipeline (622)
Policy (2)
Postmarket research (45)
Preclinical (96)
Prostate cancer (7)
Radiopharmaceuticals (10)
Rare diseases (24)
Real estate (83)
Recruiting (1)
Regulatory (416)
Reports (1)
Research institute (42)
Resumes & cover letters (3)
Rett syndrome (3)
RNA editing (1)
RSV (7)
Schizophrenia (1)
Series A (10)
Series B (11)
Service/supplier (1)
Sickle cell disease (4)
Sponsored (1)
Startups (55)
Stomach cancer (1)
Supply chain (2)
The Weekly (1)
Vaccines (28)
Venture capital (1)
Weight loss (15)
Women's health (8)
Worklife (1)
Date
Today (10)
Last 7 days (31)
Last 30 days (217)
Last 365 days (1428)
2026 (323)
2025 (1373)
2024 (1527)
2023 (1743)
2022 (1775)
2021 (1862)
2020 (1649)
2019 (1204)
2018 (1005)
2017 (845)
2016 (511)
2015 (709)
2014 (472)
2013 (317)
2012 (346)
2011 (385)
2010 (411)
Location
Africa (8)
Alabama (1)
Arizona (11)
Asia (971)
Australia (72)
California (560)
Canada (127)
China (33)
Colorado (30)
Connecticut (24)
Delaware (23)
Europe (2569)
Florida (63)
Georgia (26)
Illinois (44)
India (1)
Indiana (25)
Iowa (1)
Japan (10)
Kansas (4)
Kentucky (4)
Louisiana (7)
Maine (28)
Maryland (73)
Massachusetts (342)
Michigan (13)
Minnesota (29)
Missouri (6)
Montana (1)
Nevada (1)
New Hampshire (11)
New Jersey (154)
New York (221)
North Carolina (78)
Northern California (288)
Ohio (10)
Pennsylvania (146)
South America (27)
South Carolina (1)
Southern California (240)
Tennessee (9)
Texas (81)
United States (2016)
Utah (13)
Virginia (3)
Washington D.C. (2)
Washington State (31)
Wisconsin (5)
18,728 Results for "175".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
March 5, 2026
·
3 min read
Press Releases
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
February 1, 2026
·
7 min read
Press Releases
Mair Therapeutics Announces Scientific Collaboration with Radboud University to Advance TMEM175 Agonists for Parkinson’s Disease
January 27, 2026
·
2 min read
Press Releases
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
February 18, 2026
·
5 min read
Press Releases
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
January 8, 2026
·
6 min read
Press Releases
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
November 13, 2025
·
3 min read
Press Releases
Antheia Raises Additional $24 Million to Complete Series C Financing, Bringing Total Funds Raised to More than $175 Million Over Past Year
January 28, 2026
·
2 min read
Press Releases
Lysoway Therapeutics Announces Phase I Readiness of Brain-Penetrant TRPML1 Agonist LW-1017 and Nomination of a TMEM175 Development Candidate
January 6, 2026
·
4 min read
Press Releases
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
·
5 min read
Press Releases
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
January 14, 2026
·
5 min read
1 of 1,873
Next
